1 / 58

Slide 1

Slide 1. Presented By Mark Stein at 2014 ASCO Annual Meeting. Slide 2. Presented By Mark Stein at 2014 ASCO Annual Meeting.

warren
Download Presentation

Slide 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting

  2. Slide 2 Presented By Mark Stein at 2014 ASCO Annual Meeting

  3. <br /><br /><br /><br /><br /><br /><br />The Site of Metastases Predicts Overall Survival in Castration-Resistant Prostate Cancer Patients: A Meta-Analysis of 5 Phase III trials<br /><br />Susan Halabi1, Wm. Kevin Kelly2, Haojin Zhou1, Andrew J. Armstrong1, David I. Quinn3, Karim Fizazi4, Nicole C. Solomon1, Ian F. Tannock5, Daniel P. Petrylak6, Michael J. Morris7, Eric J. Small8 <br /><br />1Duke University, Durham, NC; 2Thomas Jefferson University, Philadelphia, PA; 3University of Southern California, Los Angeles, CA; 4Institut Gustave Roussy, Villejuif, France; 5Princess Margaret Cancer Centre, Toronto, ON, Canada; 6Yale University, New Haven, CT; 7Memorial Sloan Kettering Cancer Center, New York, NY; 8University of California San Francisco, CA<br /><br /><br /> <br /><br /> Presented By Mark Stein at 2014 ASCO Annual Meeting

  4. Patient Population (N=3,993) Presented By Mark Stein at 2014 ASCO Annual Meeting

  5. Conclusions Presented By Mark Stein at 2014 ASCO Annual Meeting

  6. Slide 6 Presented By Mark Stein at 2014 ASCO Annual Meeting

  7. PHASE iii TRIALS OF Ar targeting agents <br />PRE-ASCO 2014 Presented By Mark Stein at 2014 ASCO Annual Meeting

  8. Slide 8 Presented By Mark Stein at 2014 ASCO Annual Meeting

  9. Slide 9 Presented By Mark Stein at 2014 ASCO Annual Meeting

  10. Primary, Secondary and Quality-of-Life Endpoint Results from PREVAIL, a Phase 3 Study of Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presented By Mark Stein at 2014 ASCO Annual Meeting

  11. PREVAIL: A Phase 3 Trial of Enzalutamide After Progression on Androgen Deprivation Therapy in <br />Men with Metastatic Prostate Cancer Presented By Mark Stein at 2014 ASCO Annual Meeting

  12. Treatment Groups Were Well Balanced<br />for Baseline Patient Characteristics/Disease burden Presented By Mark Stein at 2014 ASCO Annual Meeting

  13. PHASE iii TRIALS OF Ar targeting agents <br />PRE-ASCO 2014 Presented By Mark Stein at 2014 ASCO Annual Meeting

  14. Slide 14 Presented By Mark Stein at 2014 ASCO Annual Meeting

  15. Quality-of-Life Responses by FACT-P Presented By Mark Stein at 2014 ASCO Annual Meeting

  16. <br />Most Common Adverse Events*<br /> Presented By Mark Stein at 2014 ASCO Annual Meeting

  17. Enzalutamide Had a High PSA Response Rate Presented By Mark Stein at 2014 ASCO Annual Meeting

  18. Take away Presented By Mark Stein at 2014 ASCO Annual Meeting

  19. Slide 19 Presented By Mark Stein at 2014 ASCO Annual Meeting

  20. Orteronel (TAK-700) is an investigational, non-steroidal, reversible, relatively selective inhibitor of 17,20-lyase Presented By Mark Stein at 2014 ASCO Annual Meeting

  21. PHASE iii TRIALS OF Ar targeting agents <br />PRE-ASCO 2014 Presented By Mark Stein at 2014 ASCO Annual Meeting

  22. Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial) Presented By Mark Stein at 2014 ASCO Annual Meeting

  23. Slide 23 Presented By Mark Stein at 2014 ASCO Annual Meeting

  24. Slide 24 Presented By Mark Stein at 2014 ASCO Annual Meeting

  25. Slide 25 Presented By Mark Stein at 2014 ASCO Annual Meeting

  26. Mechanisms of resistance to AR inhibition Presented By Mark Stein at 2014 ASCO Annual Meeting

  27. AR Splice Variants (AR-Vs) Presented By Mark Stein at 2014 ASCO Annual Meeting

  28. Androgen Receptor Splice Variant-7 (AR-V7) and Resistance to Enzalutamide and Abiraterone in Men with Metastatic Castration-Resistant Prostate Cancer Presented By Mark Stein at 2014 ASCO Annual Meeting

  29. Prospective Biomarker Study<br />with CTC based AR-V7 assay by RT-PCR<br /> Presented By Mark Stein at 2014 ASCO Annual Meeting

  30. Results: AR-V7 prevalence Presented By Mark Stein at 2014 ASCO Annual Meeting

  31. Take home: Presented By Mark Stein at 2014 ASCO Annual Meeting

  32. Enzalutamide in combination with Abiraterone Acetate in bone metastatic Castration Resistant Prostate Cancer Presented By Mark Stein at 2014 ASCO Annual Meeting

  33. Mechanisms of resistance to AR inhibition Presented By Mark Stein at 2014 ASCO Annual Meeting

  34. Study design Presented By Mark Stein at 2014 ASCO Annual Meeting

  35. Results: Abiraterone plus Enzalutamide Presented By Mark Stein at 2014 ASCO Annual Meeting

  36. Abiraterone plus Enzalutamide: Tissue Markers of response Presented By Mark Stein at 2014 ASCO Annual Meeting

  37. Take away: Alliance A031201 (PI: M Morris) Presented By Mark Stein at 2014 ASCO Annual Meeting

  38. Slide 38 Presented By Mark Stein at 2014 ASCO Annual Meeting

  39. Slide 39 Presented By Mark Stein at 2014 ASCO Annual Meeting

  40. Docetaxel-estramustine in localized high- risk prostate cancer: Results of the French Genito-Urinary Tumor Group GETUG 12 phase III trial Presented By Mark Stein at 2014 ASCO Annual Meeting

  41. Slide 41 Presented By Mark Stein at 2014 ASCO Annual Meeting

  42. Progression-free survival Presented By Mark Stein at 2014 ASCO Annual Meeting

  43. Additional data from early disease trials +/- docetaxel awaited Presented By Mark Stein at 2014 ASCO Annual Meeting

  44. Slide 44 Presented By Mark Stein at 2014 ASCO Annual Meeting

  45. Problem of PSA recurrence Presented By Mark Stein at 2014 ASCO Annual Meeting

  46. Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented By Mark Stein at 2014 ASCO Annual Meeting

  47. Methods. Study design. Presented By Mark Stein at 2014 ASCO Annual Meeting

  48. Take-away Presented By Mark Stein at 2014 ASCO Annual Meeting

  49. Slide 49 Presented By Mark Stein at 2014 ASCO Annual Meeting

  50. <br /><br />E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer Presented By Mark Stein at 2014 ASCO Annual Meeting

More Related